Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.
Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA.
J Vet Intern Med. 2023 Nov-Dec;37(6):2344-2355. doi: 10.1111/jvim.16915. Epub 2023 Oct 28.
The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy beagle dogs.
HYPOTHESIS/OBJECTIVES: The objectives of this study were to investigate the safety, peak plasma concentrations, and potential for efficacy of TCMCB07 in pet dogs with naturally occurring cachexia over a 4-week time period.
Fourteen dogs with cachexia of any underlying cause, except cancer of the oral cavity or gastrointestinal tract, were eligible for enrollment with informed client consent.
This study was a prospective, 1-armed open-label trial. Physical examination, complete blood count, chemistry panel, and owner-assessed quality of life surveys were checked at weeks 1, 2, and 4. Due to potential for bradycardia and hypotension, Holter monitoring and blood pressure evaluations were scheduled at pre-enrollment and week 4.
Fourteen dogs completed the trial. Significant changes detected included increased mean body weight (18.6-19.5 kg, P < .02), increased body condition score (median Tufts 5-point thin dog scale score P < .004 and WSAVA muscle condition score P < .02) and increased mean blood urea nitrogen (21.79-30.43 mg dL , P < .004). On quality of life surveys, pet owners perceived their dog appeared to be panting less (P < .002) and that the general health improved (P < .03). Four dogs had a change in coat pigmentation. The peak plasma concentration of TCMCB07 in cachectic dogs was similar to that in healthy beagle dogs.
TCMCB07 was safe and has potential efficacy in pet dogs with cachexia.
黑色素皮质素 4 拮抗剂 TCMCB07 在逆转败血症或癌症引起的啮齿动物恶病质方面安全有效。TCMCB07 在健康比格犬中的安全性和药代动力学已得到证实。
假设/目的：本研究的目的是在 4 周的时间内，研究 TCMCB07 在患有自然发生恶病质的宠物犬中的安全性、血浆峰浓度和潜在疗效。
14 只患有恶病质的犬，除口腔或胃肠道癌症外，所有潜在病因均可参加，需经知情客户同意。
这是一项前瞻性、单臂、开放标签试验。在第 1、2 和 4 周时检查体格检查、全血细胞计数、化学小组和主人评估的生活质量调查。由于潜在的心动过缓和低血压，在入组前和第 4 周安排了 Holter 监测和血压评估。
14 只狗完成了试验。检测到的显著变化包括平均体重增加（18.6-19.5kg，P<.02）、体况评分增加（Tufts 5 分瘦犬评分中位数 P<.004 和 WSAVA 肌肉状况评分 P<.02）和平均血尿素氮增加（21.79-30.43mg/dL，P<.004）。在生活质量调查中，宠物主人认为他们的狗似乎喘气少了（P<.002），一般健康状况有所改善（P<.03）。四只狗的毛色发生了变化。恶病质犬的 TCMCB07 血浆峰浓度与健康比格犬相似。
TCMCB07 在患有恶病质的宠物犬中安全且有潜在疗效。
